Drug Development

Vaccine DevelopmentVaxSkin® an innovative platform to study vaccine immunogenicityIntroduction The field of drug development is witnessing a remarkable surge in the development of innovative strategies. There is a need to develop technological platforms capable of generating human data prior to progressing to clinical trials. Developing safe and effective vaccines requires a clear understanding of early immune responses at the injectionRead more

Beyond animal models: The role of human skin in ADME testingADME (Absorption, Distribution, Metabolism, and Excretion) testing plays a vital role in modern drug development by improving candidate selection, reducing failures, enhancing safety assessments, ensuring regulatory compliance, and ultimately saving time and resources in bringing new drugs to market. Traditionally, ADME testing has relied on animal models and in vitroRead more

Top-level science through the eyes of an expert.Join us for the next session in Genoskin’s webinar series, where we explore cutting-edge advancements in drug delivery and therapeutic innovation. This session will feature an in-depth presentation on polymer prodrug nanocarriers, showcasing a novel approach to controlled and efficient drug release. This episode of Genoskin’s webinar series is scheduled on March 24th,Read more

From human skin to human data: Advancing immunogenicity testing with human modelsIn a public workshop organized by the FDA-CRCG group, Dr. Nicolas Gaudenzio, CSO of Genoskin, introduced an innovative platform for assessing immune reactions in response to injected substances using human skin explants. His talk, titled "A new in vitro framework for assessing immunogenicity using comprehensive profiling of injectable humanRead more

Skin ModelsNativeSkin®, an immunocompetent human skin model to study antigen uptake and processing by Langerhans cells Research by E. Pagès1, L. Mondoulet3, E. Bonnefont1, E. Braun1, V. Dhelft2, C. Dupont3, H. Sampson2, P. Descargues1 1Genoskin, 2DBV Technologies, 3Hôpital Necker, Université Paris-Descartes Scientific Context Epicutaneous immunotherapy (EPIT) using Viaskin® patches has been shown to induce tolerance in sensitized mice (Dioszeghy, ClinRead more

Top-level science through the eyes of an expert.The eighth Webinar. The next episode of the Genoskin Webinar series is now scheduled on October 17, 2024 at 8 a.m. (PST), 11 a.m. (EST), 5 p.m. (CET). The webinar is open to English-speaking participants with a solid scientific background. Featured speaker is Dr. Manon Scholaert, Scientist at Genoskin. Watch the replayIn thisRead more